---
title: "&#x1F535; Renal"
layout: default
nav_order: 45
---

# Renal

First time visitor? [Start here.]({% link docs/start-here.md %})

&#x1F449; Links on this page marked with a &#x1f4b2; may earn the site a modest commission.



## Generic Telmisartan Compounded Oral Oil Liquid

![Generic Telmisartan Compounded Oral Oil Liquid](https://image.chewy.com/is/image/catalog/583926_MAIN._AC_SL600_V1659906586_.jpg){: style="max-height: 144px; width: auto; float: right; margin-left: 1em;" }

[**Blood pressure**]({% link docs/blood-pressure.md %})
{: .label }
[**Drugs**]({% link docs/drugs.md %})
{: .label }
[**Proteinuria**]({% link docs/proteinuria.md %})
{: .label }
[**Renal**]({% link docs/renal.md %})
{: .label }

View on <a href="https://www.chewy.com/dp/583926" class="external" target="_blank">Chewy&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

<details markdown="block">
<summary>References and resources</summary>

1.  Committee for Medicinal Products for Veterinary Use. CVMP assessment report for Semintra to add new strength 10 mg/ml oral solution for cats to treat systemic hypertension. European Medicines Agency. 2018. <a href="https://medicines.health.europa.eu/veterinary/es/documents/download/7b45beb0-53c0-46ab-9cd0-8f4e418a6ed6" class="external" target="_blank">https://medicines.health.europa.eu/veterinary/es/documents/download/7b45beb0-53c0-46ab-9cd0-8f4e418a6ed6&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Semintra (telmisartan oral solution) 10 mg/mL product insert. Boehringer Ingelheim Animal Health USA Inc. 2019. <a href="https://docs.boehringer-ingelheim.com/PI/Theras/Semintra_PI.pdf" class="external" target="_blank">https://docs.boehringer-ingelheim.com/PI/Theras/Semintra_PI.pdf&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9. doi:<a href="https://doi.org/10.1056/NEJMoa011161" class="external" target="_blank">10.1056/NEJMoa011161&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Coleman AE, Brown SA, Traas AM, Bryson L, Zimmering T, Zimmerman A. Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial. J Vet Intern Med. 2019; 33: 478-488. doi:<a href="https://doi.org/10.1111/jvim.15429" class="external" target="_blank">10.1111/jvim.15429&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Coleman A, Elliott J. Inhibition of the renin-angiotensin-aldosterone system in cats and dogs: The emerging role of angiotensin II receptor blockers. International Renal Interest Society (IRIS). 2022. <a href="http://www.iris-kidney.com/education/renin-anglotensin-aldosterone-system.html" class="external" target="_blank">http://www.iris-kidney.com/education/renin-anglotensin-aldosterone-system.html&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Girens R, Swift S. Telmisartan for Treating Systemic Hypertension. Today's Veterinary Practice. 2019. <a href="https://todaysveterinarypractice.com/pharmacology/telmisartan-for-treating-systemic-hypertension/" class="external" target="_blank">https://todaysveterinarypractice.com/pharmacology/telmisartan-for-treating-systemic-hypertension/&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Glaus TM, Elliott J, Herberich E, Zimmering T, Albrecht B. Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial. J Vet Intern Med. 2019; 33: 413-422. doi:<a href="https://doi.org/10.1111/jvim.15394" class="external" target="_blank">10.1111/jvim.15394&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Gordon SG, Saunders AB, Malcolm E. Angiotensin II Receptor Antagonists for Use in Animals. Merck Veterinary Manual. 2023. <a href="https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-cardiovascular-system/angiotensin-ii-receptor-antagonists-for-use-in-animals" class="external" target="_blank">https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-cardiovascular-system/angiotensin-ii-receptor-antagonists-for-use-in-animals&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005 Dec;16(12):3631-41. doi:<a href="https://doi.org/10.1681/ASN.2005050522" class="external" target="_blank">10.1681/ASN.2005050522&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19(17):3033-42. doi:<a href="https://doi.org/10.2174/1381612811319170009" class="external" target="_blank">10.2174/1381612811319170009&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60. doi:<a href="https://doi.org/10.1056/NEJMoa011303" class="external" target="_blank">10.1056/NEJMoa011303&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Sent, U., GÃ¶ssl, R., Elliott, J., Syme, H.M. and Zimmering, T. (2015), Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease. J Vet Intern Med, 29: 1479-1487. doi:<a href="https://doi.org/10.1111/jvim.13639" class="external" target="_blank">10.1111/jvim.13639&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-31. doi:<a href="https://doi.org/10.1001/jama.288.19.2421" class="external" target="_blank">10.1001/jama.288.19.2421&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

</details>

* * *



## Kan Essentials Rehmannia Eight Combination

![Kan Essentials Rehmannia Eight Combination](https://kanherb.com/images/store/products/Kan_Essentials_Rehmannia_Eight_Combination_Extract.png){: style="max-height: 144px; width: auto; float: right; margin-left: 1em;" }

[**Renal**]({% link docs/renal.md %})
{: .label }
[**Supplements**]({% link docs/supplements.md %})
{: .label }

 <a href="https://kanherb.com/products/rehmannia-eight-combination/" class="external" target="_blank">manufacturer page&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

* * *


# Renal references and resources

1.  Syme HM. Cardiovascular and renal manifestations of hyperthyroidism. Vet Clin North Am Small Anim Pract. 2007 Jul;37(4):723-43, vi. doi:<a href="https://doi.org/10.1016/j.cvsm.2007.05.011" class="external" target="_blank">10.1016/j.cvsm.2007.05.011&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

<!-- Updated 2024-10-31 18:18:22.247739Z -->
